| I
|
| Drug |
CYP interaction |
Clinical consequences |
| ibuprofen
| 2C9 : substrate
| ?
|
| 2C8
| ?
|
| ifosfamide {ifosphamide} (prodrug activated by 2B1
)
| CYP2B6 : metabolism (S-) enantiomer
| ?
|
| 3A4 metabolises (R) enantiomer
| ?
|
| imipramine (See Tricyclics
| ? 1A2, 2C19; 3A4
|
|
| 2D6 : metabolism
| potential for interaction
|
| 2D6 : ? inhibits
| ?
|
| indinavir (HIV PI)
| 3A4 : metabolism
| ?
|
| 3A4 : INHIBITS
| interaction potential
|
| 2D6 : inhibits (Ki 15.6)
| ?
|
| indoramine
| 2D6 : substrate
| ?
|
| insulin
| 1A2 : INDUCES !
| ?
|
| indomethacin
| 2C19 : substrate
| ?
|
| 2C19 : INHIBITS
| ?
|
| irbesartan (AT II blocker)
| 2C19 : metabolism
| ?
|
| irinotecan (anti-tumour)
| 3A4 : metabolism
| ? interaction with ketoconazole, troleandromycin
|
| isoflurane
| CYP2E1 : METABOLISM
| ?
may inhibit eg EDHF production
|
| isoniazid (INH)
| CYP2E1 : INDUCES
(and ? metabolism)
| worsens paracetamol hepatotoxicity
|
| 2C9 : INHIBITS
| phenytoin and warfarin toxicity [Am J Med Sci 1999 May;317(5):304-11]
|
| isotretinoin
| 3A4 : inhibits (other retinoids similar: etretinate, acitretin)
| interaction with e.g. cyclosporin
|
| isradipine (see also calcium channel blockers)
| 3A4 : metabolism
| ?
|
| 2D6 : inhibits
| decreases propranolol removal [Fundam Clin Pharmacol 1994;8(4):373-8]
|
| itraconazole
See also azole antifungals
| CYP51 : INHIBITS
| ?
|
3A4 : INHIBITS
(and metabolism)
(? also inhibits 2C9)
| interaction with astemizole, terfenadine, rifampin,
oral contraceptives, H2 receptor antagonists, warfarin, cyclosporine,
tacrolimus, nifedipine, felodipine, simvastatin, lovastatin,
vincristine, [Clin Pharmacokinet 2000 Feb;38(2):111-80];
substantially reduces quinidine clearance,
also with triazolam, midazolam, alprazolam
|